Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection

New England Journal of Medicine

Volumn 369, Issue 19, 2013, Pages 1807-1818

  Walmsley, Sharon L ^a   Antela, Antonio ^b   Clumeck, Nathan ^d   Duiculescu, Dan ^e   Eberhard, Andrea ^f   Gutieŕrez, Felix ^c   Hocqueloux, Laurent ^g   Maggiolo, Franco ^h   Sandkovsky, Uriel ⁱ   Granier, Catherine ^j   Pappa, Keith ^k   Wynne, Brian ^k   Min, Sherene ^k   Nichols, Garrett ^k  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^f MVZ Karlsplatz HIV Research and Clinical Care Center   (Germany)

^g CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^h OSPEDALI RIUNITI   (Italy)

ⁱ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DOLUTEGRAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; VIRUS RNA;

ABNORMAL DREAMING; ADULT; ANTIVIRAL RESISTANCE; ANXIETY DISORDER; ARTICLE; BRONCHITIS; CD4+ T LYMPHOCYTE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUTATION; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SOMNOLENCE; SUBCUTANEOUS TISSUE DISORDER; TREATMENT OUTCOME;

EID: 84887052771     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1215541     Document Type: Article

References (35)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents (http://aidsinfo.nih. gov/contentfiles/lvguidelines/adultandadolescentgl.pdf).
2. ThompsonMA, AbergJA, HoyJF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
3. European AIDS Clinical Society guidelines, version 7.0 - October 2013. Paris: European AIDS Clinical Society (http://www.eacsociety.org/Portals/0/ Guidelines-Online-131014.pdf).
4. RozenbaumW, KatlamaC, MassipP, et al. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Antivir Ther 2001;6:135-42.
5. KatlamaC, FenskeS, GazzardB, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86.
6. MinS, SongI, BorlandJ, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8.
7. van LunzenJ, MaggioloF, ArribasJR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12:111-8.
8. HightowerKE, WangR, DeandaF, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55:4552-9.
9. EronJJ, ClotetB, DurantJ, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013;207:740-8.
10. Declaration of Helsinki: ethical principles for medical research involving human subjects. Ferney-Voltaire, France: World Medical Association, 2008 (http://www.wma.net/en/30publications/10policies/b3/17c.pdf).
11. MallalS, PhillipsE, CarosiG, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
12. RaffiF, RachlisA, StellbrinkHJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43.
13. SaxPE, DeJesusE, MillsA, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379:2439-48. [Erratum, Lancet 2012;380:730.]
14. DeJesusE, RockstrohJK, HenryK, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379:2429-38.
15. SmithF, HammerstromT, SoonG, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 2011;45:291-300.
16. Division of AIDS table for grading the severity of adult and pediatric adverse events: version 1.0, December 2004; clarification August 2009. Bethesda, MD: Division of AIDS, 2009 (http://rsc.tech-res.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult-Pediatric- Adverse-Events.pdf).
17. JusticeAC, HolmesW, GiffordAL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001;54:Suppl 1:S77-S90.
18. MarcLG, WangMM, TestaMA. Psychometric evaluation of the HIV symptom distress scale. AIDS Care 2012;24:1432-41.
19. HillA, SabinC. Designing and interpreting HIV noninferiority trials in naive and experienced patients. AIDS 2008;22:913-21.
20. SatoT. On the variance estimator for the Mantel-Haenszel risk difference. Biometrics 1989;42:311-23.
21. WiensBL, DmitrienkoA. The fallback procedure for evaluating a single family of hypotheses. J Biopharm Stat 2005;15:929-42.
22. DmitrienkoA, TamhaneAC, WiensBL. General multistage gatekeeping procedures. Biom J 2008;50:667-77.
23. StellbrinkH-J, ReynesJ, LazzarinA, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013;27:1771-8.
24. LennoxJL, DeJesusE, LazzarinA, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Errata, Lancet 2009;374:786, 2054.]
25. ScourfieldA, ZhengJ, ChinthapalliS, et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012;26:1399-401.
26. Atripla. Princeton, NJ: Bristol-Myers Squibb, 2012 (package insert).
27. KoteffJ, BorlandJ, ChenS, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013;75:990-6.
28. AndreevE, KoopmanM, AriszL. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999;246:247-52.
29. LepistEI, MurrayBP, TongL, RoyA, BannisterR, RayAS. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 17-20, 2011. abstract.
30. CohenCJ, Andrade-VillanuevaJ, ClotetB, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-37.
31. MolinaJM, CahnP, GrinsztejnB, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-46.
32. KobayashiM, YoshinagaT, SekiT, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55:813-21.
33. CahnP, PozniakAL, MingroneH, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382:700-8.
34. NicholsG, LazzarinA, MaggioloF, et al. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled. Presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Kuala Lumpur, Malaysia, June 30-July 3, 2013. abstract TULBPE19.
35. RaffiF, JaegerH, Quiros-RoldanE, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13:927-35.